Our Blog

20 September 2019

Do JAK inhibitors have potential in blood and bone marrow cancers?

adult-aging-bottle-1389104 (3)

In a recent survey conducted by Bryter, it was found that six-in-10 hematologists agreed that JAK inhibitors have the potential to be a breakthrough treatment for blood and bone marrow cancers.

This likely stems from the fact that they are an orally administered agent, targeting the JAK-STAT pathway. Aberrant JAK/STAT signaling has been identified to contribute to cancer progression and metastatic development. 

The scientific community is currently investigating which blood and bone marrow cancers could most benefit from JAK inhibitors. So far, potential has been seen in myeloproliferative neoplasms such as myelofibrosis and polycythemia vera.

Toxicity is however a concern. Last year it was found that JAK inhibitors being used to treat myelofibrosis may lead to the development of lymphomas.

Bryter explored the impact of this further in their survey, which revealed that of the 50% of hematologists who were aware of the finding, half reported concern about the toxicity profile/ safety of JAK inhibitors. 

Further details are highlighted in Bryter’s full article, which further explores hematologists’ thoughts on where the best potential for JAK inhibitors lies and any concerns around toxicity that they might have. Click on the link below to download the full results and analysis

Download the Bryter JAK Survey




Have a question? Need advice on how research and insight can support your business objectives?

Book a discovery call with one of our consultants to

  • - Discuss your business challenge or question
  • - Hear how Bryter can address your business needs
  • - Hear more about our different services, solutions and case studies

Click on schedule a meeting to book your call.

Related Posts

MCDA in IBD: Helping Us Unpick Multi-Level Decision Making Even with Small Sample Sizes

At Bryter Labs, we are always experimenting with new techniques for market research. We’re passionate about providing th...

Read More

3 Key Takeaways from the Digital Pharma Advances Conference

The pharma industry is seeing increasingly rapid change in the digital space. Last week Bryter attended the Digital Phar...

Read More

What if there were 100 people on earth living with cancer?

The International Agency for Research on Cancer (IARC) estimates that there were 17 million new cancer cases in 2018 wor...

Read More


Bryter is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account .